gatifloxacin has been researched along with garenoxacin in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (85.71) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Bronstein, JC; Domagala, JM; Dunham, SA; Ellsworth, EL; Gage, JW; Gracheck, SJ; Hanna, DL; Huband, MD; Joannides, ET; Liu, JY; Nguyen, DQ; Sanchez, JP; Shapiro, MA; Showalter, HD; Singh, R; Stier, MA; Tran, TP; Watson, BM | 1 |
| Cohen, MA; Ellsworth, E; Gage, JW; Gibson, GW; Gracheck, SJ; Hanna, DL; Huband, MD; Skerlos, LA; Stier, MA; Sulavik, MC; Zurack, M | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Sasaki, T; Takahata, M; Yamazaki, T | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S | 1 |
| Daw-Garza, A; Lozano-Garza, HG; Ocampo-Candiani, J; Rocha, NC; Said-Fernández, S; Vera-Cabrera, L; Waksman de Torres, N; Welsh, O | 1 |
| Ho, YR; Hung, KH; Janapatla, RP; Wu, CW; Wu, HM; Wu, JJ; Yan, JJ | 1 |
| Hibi, T; Muraoka, H; Nishizawa, T; Suzuki, H | 1 |
| Hirakata, Y; Imamura, Y; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Seki, M; Sugahara, K; Yamamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Distèche-Nguyen, M; Gerards, T; Luxen, A; Miguet, L; Pasha, FA; Thomas, A; Zervosen, A | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Brady, SF; Koirala, B; Peek, J | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Anderegg, TR; Biedenbach, DJ; Jones, RN | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Piddock, L; Ricci, V | 1 |
| Almaraz, F; Baquero, F; Cantón, R; Jones, RN; Loza, E; Martín, R; Morosini, MI; Pascual, A; Perea, E; Tubau, F | 1 |
| Bébéar, C; Bébéar, CM; Pereyre, S; Renaudin, H | 1 |
| Gidoh, M | 1 |
| Hsu, MC; Leunk, R; Makin, K; Roychoudhury, S; Twinem, T | 1 |
1 review(s) available for gatifloxacin and garenoxacin
| Article | Year |
|---|---|
Quinolone antibiotics.
Topics: | 2019 |
20 other study(ies) available for gatifloxacin and garenoxacin
| Article | Year |
|---|---|
3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.
Topics: Anti-Bacterial Agents; Bacteria; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Methicillin Resistance; Microbial Sensitivity Tests; Quinazolinones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2006 |
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Pyrrolidines; Quinazolinones; Topoisomerase II Inhibitors | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Macrolides; Microbial Sensitivity Tests; Mycoplasma pneumoniae | 2007 |
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium leprae | 2008 |
In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Mice; Mice, Inbred BALB C; Nocardia; Nocardia Infections; Oxazolidinones; Treatment Outcome | 2008 |
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
Topics: Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Streptococcus agalactiae; Taiwan | 2008 |
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Helicobacter pylori; Mutation | 2009 |
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
Discovery of new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP) 2x by structure-based virtual screening.
Topics: Computational Biology; Computer Simulation; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Ligands; Penicillin-Binding Proteins; Protein Binding; Streptococcus pneumoniae; Structure-Activity Relationship | 2009 |
Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; HEK293 Cells; Humans; Microbial Sensitivity Tests; Rifamycins; Staphylococcus aureus | 2022 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Guidelines as Topic; Haemophilus influenzae; Humans; Indoles; Microbial Sensitivity Tests; Quality Control; Quinolones; Sensitivity and Specificity; Streptococcus pneumoniae | 2003 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
[Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Species Specificity; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma Infections; Naphthyridines; Quinolones | 2004 |
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin | 2007 |
In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression; Microbial Sensitivity Tests; Mutation; Quinolones; Sequence Analysis, DNA; Streptococcus pneumoniae; Structure-Activity Relationship | 2016 |